The association between patient characteristics and letermovir use
| Characteristics . | Patients with letermovir prophylaxis (n = 236) . | Patients without CMV prophylaxis (n = 1958) . | P value . |
|---|---|---|---|
| Patient age at HSCT, y, median | 54.0 | 51.0 | <.001 |
| Sex mismatch | .74 | ||
| Female to male | 48 (20.3%) | 419 (21.4%) | |
| Other | 188 (79.7%) | 1539 (78.6%) | |
| Underlying disease | .24 | ||
| Acute myeloid leukemia | 104 (44.1%) | 867 (44.3%) | |
| Acute lymphoblastic leukemia | 47 (19.9%) | 341 (17.4%) | |
| Aplastic anemia | 9 (3.8%) | 50 (2.6%) | |
| Chronic myeloid leukemia | 3 (1.3%) | 75 (3.8%) | |
| Myelodysplastic syndromes | 36 (15.3%) | 327 (16.7%) | |
| Other | 11 (4.7%) | 93 (4.7%) | |
| Disease risk | .84 | ||
| Low | 109 (46.2%) | 909 (46.4%) | |
| High | 127 (53.8%) | 1027 (52.5%) | |
| NA | 0 | 22 (1.1%) | |
| Number of HSCTs | .93 | ||
| 1 | 193 (81.8%) | 1590 (81.2%) | |
| 2 | 43 (18.2%) | 368 (18.8%) | |
| Graft source | .004 | ||
| BM | 80 (33.9%) | 868 (44.3%) | |
| PBSCs | 75 (31.8%) | 582 (29.7%) | |
| CB | 81 (34.3%) | 508 (25.9%) | |
| HLA | .009 | ||
| Matched | 76 (32.2%) | 804 (41.1%) | |
| Mismatched | 160 (67.8%) | 1154 (58.9%) | |
| Relationship | .77 | ||
| Related | 75 (31.8%) | 644 (32.9%) | |
| Unrelated | 161 (68.2%) | 1314 (67.1%) | |
| Performance status | .51 | ||
| 0-1 | 214 (90.7%) | 1741 (88.9%) | |
| 2-4 | 22 (9.3%) | 217 (11.1%) | |
| HCT-CI | .36 | ||
| 0-2 | 178 (75.4%) | 1531 (78.2%) | |
| ≥3 | 58 (24.6%) | 427 (21.8%) | |
| Donor CMV IgG | .006 | ||
| Positive | 98 (41.5%) | 750 (38.3%) | |
| Negative | 63 (26.7%) | 767 (39.2%) | |
| Unknown | 75 (31.8%) | 441 (22.5%) | |
| Conditioning intensity | .098 | ||
| Myeloablative | 109 (46.2%) | 1020 (52.1%) | |
| Reduced intensity | 127 (53.8%) | 938 (47.9%) | |
| ATG use before HSCT | <.001 | ||
| Yes | 66 (28.0%) | 323 (16.5%) | |
| No | 170 (72.0%) | 1635 (83.5%) | |
| Acute GVHD, grade | 1.0 | ||
| 0-1 | 148 (62.7%) | 1197 (61.1%) | |
| 2-4 | 86 (36.4%) | 699 (35.7%) | |
| NA | 2 (0.8%) | 62 (3.2%) |
| Characteristics . | Patients with letermovir prophylaxis (n = 236) . | Patients without CMV prophylaxis (n = 1958) . | P value . |
|---|---|---|---|
| Patient age at HSCT, y, median | 54.0 | 51.0 | <.001 |
| Sex mismatch | .74 | ||
| Female to male | 48 (20.3%) | 419 (21.4%) | |
| Other | 188 (79.7%) | 1539 (78.6%) | |
| Underlying disease | .24 | ||
| Acute myeloid leukemia | 104 (44.1%) | 867 (44.3%) | |
| Acute lymphoblastic leukemia | 47 (19.9%) | 341 (17.4%) | |
| Aplastic anemia | 9 (3.8%) | 50 (2.6%) | |
| Chronic myeloid leukemia | 3 (1.3%) | 75 (3.8%) | |
| Myelodysplastic syndromes | 36 (15.3%) | 327 (16.7%) | |
| Other | 11 (4.7%) | 93 (4.7%) | |
| Disease risk | .84 | ||
| Low | 109 (46.2%) | 909 (46.4%) | |
| High | 127 (53.8%) | 1027 (52.5%) | |
| NA | 0 | 22 (1.1%) | |
| Number of HSCTs | .93 | ||
| 1 | 193 (81.8%) | 1590 (81.2%) | |
| 2 | 43 (18.2%) | 368 (18.8%) | |
| Graft source | .004 | ||
| BM | 80 (33.9%) | 868 (44.3%) | |
| PBSCs | 75 (31.8%) | 582 (29.7%) | |
| CB | 81 (34.3%) | 508 (25.9%) | |
| HLA | .009 | ||
| Matched | 76 (32.2%) | 804 (41.1%) | |
| Mismatched | 160 (67.8%) | 1154 (58.9%) | |
| Relationship | .77 | ||
| Related | 75 (31.8%) | 644 (32.9%) | |
| Unrelated | 161 (68.2%) | 1314 (67.1%) | |
| Performance status | .51 | ||
| 0-1 | 214 (90.7%) | 1741 (88.9%) | |
| 2-4 | 22 (9.3%) | 217 (11.1%) | |
| HCT-CI | .36 | ||
| 0-2 | 178 (75.4%) | 1531 (78.2%) | |
| ≥3 | 58 (24.6%) | 427 (21.8%) | |
| Donor CMV IgG | .006 | ||
| Positive | 98 (41.5%) | 750 (38.3%) | |
| Negative | 63 (26.7%) | 767 (39.2%) | |
| Unknown | 75 (31.8%) | 441 (22.5%) | |
| Conditioning intensity | .098 | ||
| Myeloablative | 109 (46.2%) | 1020 (52.1%) | |
| Reduced intensity | 127 (53.8%) | 938 (47.9%) | |
| ATG use before HSCT | <.001 | ||
| Yes | 66 (28.0%) | 323 (16.5%) | |
| No | 170 (72.0%) | 1635 (83.5%) | |
| Acute GVHD, grade | 1.0 | ||
| 0-1 | 148 (62.7%) | 1197 (61.1%) | |
| 2-4 | 86 (36.4%) | 699 (35.7%) | |
| NA | 2 (0.8%) | 62 (3.2%) |
HCT-CI, hematopoietic cell transplantation-specific comorbidity index; NA, not assessed.